Altogether, the dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes compared with gefitinib alone for second-line therapy of advanced NSCLC.[3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.